IP Library Granted Patent US 11,246,891
Granted Patent B2
US 11,246,891 · App. 16/780,718 · Granted Feb 15, 2022

Compositions and methods for treating and preventing tissue injury and disease

Inventors: Dale R. Peterson (Carlsbad, CA); Ralph-Heiko Mattern (Ramona, CA); Kevin L. Ohashi (Jamaica Plain, MA); Lael J. Pickett (White Bear Lake, MN); Glen Gong (San Carlos, CA); Mohammad A. El-Kalay (Carlsbad, CA)
Assignee: Micro Vascular Tissues, Inc.
A61K35/44A61K35/12A61K35/545A61L27/3625A61L27/3687A61L27/3691A61L27/3834A61L27/3878A61L27/54C12N5/0653A61L2300/41A61L2300/412A61L2400/06A61L2430/02A61L2430/06A61L2430/10A61L2430/32A61L2430/34A61L2430/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,246,891
App. No.
16/780,718
Granted
Feb 15, 2022
Kind
B2
Abstract

The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.

Claims (30)

1. A method of treating an injury in a subject in need thereof, comprising administering a therapeutic agent to a subject in need thereof, wherein the therapeutic agent comprises enriched, sterilized multipotent cells, wherein the multipotent cells are sterilized by irradiation.

2. The method of claim 1 , wherein the injury is a soft-tissue injury.

3. The method of claim 2 , wherein the soft-tissue injury is ischemic.

4. The method of claim 2 , wherein the soft-tissue injury is tendinopathy.

5. The method of claim 2 , wherein the soft-tissue injury is in a ligament.

6. The method of claim 2 , wherein the soft-tissue injury is in muscle, synovium, or adipose tissue.

7. The method of claim 1 , wherein the injury is a bone defect or bone void.

8. The method of claim 1 , wherein the multipotent cells have been isolated from microvascular tissue.

9. The method of claim 1 , wherein the multipotent cells have been enriched by removal of extraneous tissue.

10. The method of claim 1 , wherein the multipotent cells have been enriched by culturing the multipotent cells.

11. The method of claim 1 , wherein administering the therapeutic agent comprises injection or surgical application to the region of injury.

12. The method of claim 1 , wherein administering the therapeutic agent comprises systemic injection.

13. The method of claim 2 , wherein the therapeutic agent is a powder, gel or ointment applied topically near the site of soft-tissue injury.

14. The method of claim 2 , wherein the soft-tissue injury is a wound.

15. The method of claim 14 , wherein the wound is selected from the group consisting of a surgical wound, a burn, a radiation burn, a diabetic wound, a pressure ulcer, a venous ulcer and a diabetic ulcer.

16. A method of treating an injury in a subject in need thereof, comprising administering a therapeutic agent to a subject in need thereof, wherein the therapeutic agent comprises enriched, sterilized multipotent cells, wherein the sterilized multipotent cells are nonviable.

17. The method of claim 16 , wherein the injury is a soft-tissue injury.

18. The method of claim 17 , wherein the soft-tissue injury is ischemic.

19. The method of claim 17 , wherein the soft-tissue injury is tendinopathy.

20. The method of claim 17 , wherein the soft-tissue injury is in a ligament.

21. The method of claim 17 , wherein the soft-tissue injury is in muscle, synovium, or adipose tissue.

22. The method of claim 16 , wherein the injury is a bone defect or bone void.

23. The method of claim 16 , wherein the multipotent cells have been isolated from microvascular tissue.

24. The method of claim 16 , wherein the multipotent cells have been enriched by removal of extraneous tissue.

25. The method of claim 16 , wherein the multipotent cells have been enriched by culturing the multipotent cells.

26. The method of claim 16 , wherein administering the therapeutic agent comprises injection or surgical application to the region of injury.

27. The method of claim 16 , wherein administering the therapeutic agent comprises systemic injection.

28. The method of claim 17 , wherein the therapeutic agent is a powder, gel or ointment applied topically near the site of soft-tissue injury.

29. The method of claim 17 , wherein the soft-tissue injury is a wound.

30. The method of claim 14 , wherein the wound is selected from the group consisting of a surgical wound, a burn, a radiation burn, a diabetic wound, a pressure ulcer, a venous ulcer and a diabetic ulcer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2021
From: PETERSON, DALE R.; MATTERN, RALPH-HEIKO; OHASHI, KEVIN L.; PICKETT, LAEL J.; GONG, GLEN; EL-KALAY, MOHAMMAD A.
To: MICROVASCULAR TISSUES, INC.
Reel/Frame 054876/0513 →
Continuity (5)
Division 15865220 · Jan 8, 2018
Continuation In Part 15633311 · Jun 26, 2017
Continuation 14426511
Provisional Application 61703203 · Sep 19, 2012
Related Publication 20200323925A1 · Oct 15, 2020
Cited By (1)
US 12,364,716